Erlotinib selectively targets the ATP binding site within the cytoplasmic tyrosine kinase domain of the EGFR protein and disrupt the kinase activity, and is approved for treatment of Non-small cell lung cancer (NSCLC) as well as investigational in other types of cancers61,62. Here, EGFR is linked to non-small cell lung carcinoma.